Eton Pharmaceuticals, Inc. Operating Lease Right-of-Use Assets
Eton Pharmaceuticals, Inc. (ETON) had Operating Lease Right-of-Use Assets of $1.11 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $1.11M.
- 2026-05-31: Operating Lease, Right-of-Use Asset $849.00K.
- 2026-03-31: Operating Lease, Right-of-Use Asset $301.00K.
- 2025-12-31: Operating Lease, Right-of-Use Asset $310.00K.
| Period end | Operating Lease, Right-of-Use Asset | Operating Lease, Right-of-Use Asset as first filed |
|---|---|---|
| 2026-06-30 | $1.11M 10-Q · filed 2026-08-13 | |
| 2026-05-31 | $849.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $301.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $310.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $319.00K 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $324.00K 10-Q · filed 2025-08-07 | |
| 2025-05-31 | $333.00K 10-Q · filed 2026-08-13 | |
| 2025-05-30 | $333.00K 10-Q · filed 2026-05-14 | |
| 2025-03-31 | $158.00K 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $175.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | $193.00K 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $219.00K 10-K · filed 2026-03-19 | $210.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $74.00K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $92.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $109.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $149.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $169.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $188.00K 10-K · filed 2024-03-14 | |
| 2022-11-30 | $188.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $42.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $63.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $84.00K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $104.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $123.00K 10-Q · filed 2021-11-16 | |
| 2021-06-30 | $143.00K 10-Q · filed 2021-08-16 | |
| 2021-03-31 | $84.00K 10-Q · filed 2022-05-12 | $163.00K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $192.00K 10-K · filed 2022-03-16 | |
| 2020-10-31 | $195.00K 10-K · filed 2024-03-14 | |
| 2020-09-30 | $63.00K 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $96.00K 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $129.00K 10-Q · filed 2020-05-14 | |
| 2019-12-31 | $160.00K 10-K · filed 2021-03-16 | |
| 2019-09-30 | $191.00K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $222.00K 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $252.00K 10-Q · filed 2019-05-07 | |
| 2019-01-02 | $281.00K 10-K · filed 2020-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |